A novel high throughput approach to screen for cardiac arrhythmic events following stem cell treatment

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Although stem cell therapy is promising for repairing damaged cardiac tissue and improving heart function, there are safety concerns, especially regarding the risk of arrhythmias, which can be life threatening. To address this issue, we propose to develop a novel screening system to evaluate arrhythmic risk associated with stem cell therapy using a high-throughput multielectrode array system that can measure conduction velocity and action potential duration in cardiomyocytes co-cultured with different types of stem cells, such as mesenchymal stem cells, skeletal myoblasts, and resident cardiac stem cells. We will assess the arrhythmic potential of each of these types of stem cells under normoxic and hypoxic conditions, with/without application of oxidative stress or catecholamines. We hypothesize that these methods will prove to be an effective way to screen for arrhythmic risk of cardiac stem cell therapy. Ultimately, our approach can potentially be personalized to develop a robust screening protocol in order to identify which stem cell type carries the least amount of risk for arrhythmia. This system will have great clinical benefit to improve the risk/benefit ratio of human stem cell therapy for heart disease.

Original languageEnglish (US)
Pages (from-to)294-297
Number of pages4
JournalMedical Hypotheses
Volume84
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Stem Cells
Cell- and Tissue-Based Therapy
Therapeutics
Cardiac Arrhythmias
Skeletal Myoblasts
Mesenchymal Stromal Cells
Cardiac Myocytes
Action Potentials
Catecholamines
Heart Diseases
Oxidative Stress
Odds Ratio
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{d8254cf55daf4427a408de75ec20c7dd,
title = "A novel high throughput approach to screen for cardiac arrhythmic events following stem cell treatment",
abstract = "Although stem cell therapy is promising for repairing damaged cardiac tissue and improving heart function, there are safety concerns, especially regarding the risk of arrhythmias, which can be life threatening. To address this issue, we propose to develop a novel screening system to evaluate arrhythmic risk associated with stem cell therapy using a high-throughput multielectrode array system that can measure conduction velocity and action potential duration in cardiomyocytes co-cultured with different types of stem cells, such as mesenchymal stem cells, skeletal myoblasts, and resident cardiac stem cells. We will assess the arrhythmic potential of each of these types of stem cells under normoxic and hypoxic conditions, with/without application of oxidative stress or catecholamines. We hypothesize that these methods will prove to be an effective way to screen for arrhythmic risk of cardiac stem cell therapy. Ultimately, our approach can potentially be personalized to develop a robust screening protocol in order to identify which stem cell type carries the least amount of risk for arrhythmia. This system will have great clinical benefit to improve the risk/benefit ratio of human stem cell therapy for heart disease.",
author = "William Tung and Weintraub, {Neal Lee} and Berman, {Adam Eric} and Tang, {Yao Liang}",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.mehy.2015.01.015",
language = "English (US)",
volume = "84",
pages = "294--297",
journal = "Medical Hypotheses",
issn = "0306-9877",
publisher = "Churchill Livingstone",
number = "4",

}

TY - JOUR

T1 - A novel high throughput approach to screen for cardiac arrhythmic events following stem cell treatment

AU - Tung, William

AU - Weintraub, Neal Lee

AU - Berman, Adam Eric

AU - Tang, Yao Liang

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Although stem cell therapy is promising for repairing damaged cardiac tissue and improving heart function, there are safety concerns, especially regarding the risk of arrhythmias, which can be life threatening. To address this issue, we propose to develop a novel screening system to evaluate arrhythmic risk associated with stem cell therapy using a high-throughput multielectrode array system that can measure conduction velocity and action potential duration in cardiomyocytes co-cultured with different types of stem cells, such as mesenchymal stem cells, skeletal myoblasts, and resident cardiac stem cells. We will assess the arrhythmic potential of each of these types of stem cells under normoxic and hypoxic conditions, with/without application of oxidative stress or catecholamines. We hypothesize that these methods will prove to be an effective way to screen for arrhythmic risk of cardiac stem cell therapy. Ultimately, our approach can potentially be personalized to develop a robust screening protocol in order to identify which stem cell type carries the least amount of risk for arrhythmia. This system will have great clinical benefit to improve the risk/benefit ratio of human stem cell therapy for heart disease.

AB - Although stem cell therapy is promising for repairing damaged cardiac tissue and improving heart function, there are safety concerns, especially regarding the risk of arrhythmias, which can be life threatening. To address this issue, we propose to develop a novel screening system to evaluate arrhythmic risk associated with stem cell therapy using a high-throughput multielectrode array system that can measure conduction velocity and action potential duration in cardiomyocytes co-cultured with different types of stem cells, such as mesenchymal stem cells, skeletal myoblasts, and resident cardiac stem cells. We will assess the arrhythmic potential of each of these types of stem cells under normoxic and hypoxic conditions, with/without application of oxidative stress or catecholamines. We hypothesize that these methods will prove to be an effective way to screen for arrhythmic risk of cardiac stem cell therapy. Ultimately, our approach can potentially be personalized to develop a robust screening protocol in order to identify which stem cell type carries the least amount of risk for arrhythmia. This system will have great clinical benefit to improve the risk/benefit ratio of human stem cell therapy for heart disease.

UR - http://www.scopus.com/inward/record.url?scp=84924040898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924040898&partnerID=8YFLogxK

U2 - 10.1016/j.mehy.2015.01.015

DO - 10.1016/j.mehy.2015.01.015

M3 - Article

VL - 84

SP - 294

EP - 297

JO - Medical Hypotheses

JF - Medical Hypotheses

SN - 0306-9877

IS - 4

ER -